{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T12:05:55Z","timestamp":1768133155863,"version":"3.49.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clml.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T18:29:41Z","timestamp":1737484181000},"page":"421-431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions: Combination Therapy in Chronic Myeloid Leukemia in Chronic Phase"],"prefix":"10.1016","volume":"25","author":[{"given":"Alessandro","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clml.2025.01.004_bib0001","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bj\u00f6rkholm","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.01.004_bib0002","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of Imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.01.004_bib0003","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: eNESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2025.01.004_bib0004","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.01.004_bib0005","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.19269","article-title":"How to improve treatment-free remission eligibility in chronic myeloid leukaemia?","volume":"204","author":"Costa","year":"2024","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2025.01.004_bib0006","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1002\/cam4.3071","article-title":"How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA)","volume":"9","author":"Breccia","year":"2020","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0007","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.004_bib0008","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1182\/blood-2023-178790","article-title":"Long-term results from the optic trial: a dose-optimization study of 3 starting doses of Ponatinib","volume":"142","author":"Cortes","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.01.004_bib0009","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.004_bib0010","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1182\/blood-2023-186854","volume":"142","author":"Mauro","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.01.004_bib0011","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","article-title":"Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u22651 prior tyrosine kinase inhibitor: 2-year follow-up results","volume":"38","author":"Cortes","year":"2024","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.01.004_bib0012","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2025.01.004_bib0013","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.2023022538","article-title":"BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib","volume":"144","author":"Leyte-Vidal","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.01.004_bib0014","doi-asserted-by":"crossref","first-page":"eabe4038","DOI":"10.1126\/sciadv.abe4038","article-title":"Patient-tailored design for selective co-inhibition of leukemic cell subpopulations","volume":"7","author":"Ianevski","year":"2021","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0015","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1038\/s41467-022-29793-5","article-title":"Bipartite network models to design combination therapies in acute myeloid leukaemia","volume":"13","author":"Jafari","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-024-00571-2","article-title":"A network-based trans-omics approach for predicting synergistic drug combinations","volume":"4","author":"Iida","year":"2024","journal-title":"Commun Med"},{"issue":"2","key":"10.1016\/j.clml.2025.01.004_bib0017","doi-asserted-by":"crossref","first-page":"bbae015","DOI":"10.1093\/bib\/bbae015","article-title":"SynergyX: a multi-modality mutual attention network for interpretable drug synergy prediction","volume":"25","author":"Guo","year":"2024","journal-title":"Brief Bioinform"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41389-024-00510-9","article-title":"Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy\/toxicity integration and bipartite network modeling","volume":"13","author":"Mirzaie","year":"2024","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0019","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","volume":"2009","author":"Bixby","year":"2009","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.clml.2025.01.004_bib0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14656566.2024.2331778","article-title":"Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors","volume":"25","author":"Costa","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0021","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.clml.2025.01.004_bib0022","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.01.004_bib0023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/sj.leu.2403649","article-title":"Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease","volume":"19","author":"Eisterer","year":"2005","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.clml.2025.01.004_bib0024","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.004_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00194","article-title":"Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission","volume":"8","author":"Bocchia","year":"2018","journal-title":"Front Oncol"},{"issue":"37","key":"10.1016\/j.clml.2025.01.004_bib0026","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.1073\/pnas.1004408107","article-title":"Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein","volume":"107","author":"J\u00e4r\u00e5s","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.clml.2025.01.004_bib0027","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.01.004_bib0028","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2014-07-585943","article-title":"Targeting the JAK2-STAT5 pathway in CML","volume":"124","author":"Valent","year":"2014","journal-title":"Blood"},{"issue":"7281","key":"10.1016\/j.clml.2025.01.004_bib0029","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-\u03b2\u2013FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-012-0150-1","article-title":"Signal transduction in the chronic leukemias: implications for targeted therapies","volume":"8","author":"Ahmed","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"10.1016\/j.clml.2025.01.004_bib0031","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells In vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0032","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ccr.2010.04.025","article-title":"Wnt\/Ca2+\/NFAT signaling maintains survival of ph+ leukemia cells upon inhibition of bcr-abl","volume":"18","author":"Gregory","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.clml.2025.01.004_bib0033","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.stem.2015.02.014","article-title":"Normal and leukemic stem cell niches: insights and therapeutic opportunities","volume":"16","author":"Schepers","year":"2015","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0034","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","article-title":"Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia","volume":"21","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2025.01.004_bib0035","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-97746-1_6","article-title":"Preservation of quiescent chronic myelogenous leukemia stem cells by the bone marrow microenvironment","volume":"1100","author":"Shah","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-04842-5","article-title":"Mitochondrial oxidative phosphorylation is dispensable for survival of CD34+ chronic myeloid leukemia stem and progenitor cells","volume":"13","author":"Yan","year":"2022","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.1016\/j.clml.2025.01.004_bib0037","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0038","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12013-014-0434-2","article-title":"HIF-\u03b1 promotes chronic myelogenous leukemia cell proliferation by upregulating p21 expression","volume":"72","author":"Chen","year":"2015","journal-title":"Cell Biochem Biophys"},{"issue":"6","key":"10.1016\/j.clml.2025.01.004_bib0039","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1182\/blood.2022018196","article-title":"Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells","volume":"142","author":"Qiu","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.01.004_bib0040","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-14-3379","article-title":"Microenvironmental remodeling as a parameter and prognostic factor of heterogeneous leukemogenesis in acute myelogenous leukemia","volume":"75","author":"Kim","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0041","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells","volume":"7","author":"Jin","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.clml.2025.01.004_bib0042","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-019-0427-7","article-title":"Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling","volume":"33","author":"Kuepper","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.01.004_bib0043","first-page":"235","article-title":"CD44, Hyaluronan, the hematopoietic stem cell, and leukemia-initiating cells","volume":"6","author":"Z\u00f6ller","year":"2015","journal-title":"Front Immunol"},{"issue":"19","key":"10.1016\/j.clml.2025.01.004_bib0044","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2013-02-485607","article-title":"Autocrine TNF-\u03b1 production supports CML stem and progenitor cell survival and enhances their proliferation","volume":"122","author":"Gallipoli","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.01.004_bib0045","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood.V62.3.689.689","article-title":"Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia","volume":"62","author":"Talpaz","year":"1983","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.01.004_bib0046","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon Alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials","volume":"89","year":"1997","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.clml.2025.01.004_bib0047","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.01.004_bib0048","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2025.01.004_bib0049","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.01.004_bib0050","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/s41375-020-01117-w","article-title":"Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial","volume":"35","author":"Guilhot","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2025.01.004_bib0051","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-\u03b1 in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.01.004_bib0052","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with Imatinib, predicts survival, and is achieved more quickly by optimized high-dose Imatinib: results from the randomized CML-Study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.01.004_bib0053","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.01.004_bib0054","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/ejh.13699","article-title":"Long-term tolerability and efficacy after initial PegIFN-\u03b1 addition to dasatinib in CML-CP: five-year follow-up of the NordCML007 study","volume":"107","author":"Flygt","year":"2021","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.004_bib0055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bjh.18486","article-title":"Dasatinib plus Peg-interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: results of a multicenter phase 2 study (DASA-PegIFN study)","volume":"200","author":"Roy","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.01.004_bib0056","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00277-023-05199-1","article-title":"Switching from imatinib to nilotinib plus pegylated interferon-\u03b12b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects","volume":"102","author":"Geelen","year":"2023","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.004_bib0057","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood-2021-146412","article-title":"Treatment-free remissions in newly diagnosed CP CML patients treated with the combination of Nilotinib + pegylated interferon alpha 2a versus Nilotinib alone in the national Phase III petals trial","volume":"138","author":"Nicolini","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.004_bib0058","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2019-123674","article-title":"The combination of Nilotinib + pegylated IFN alpha 2a provides somewhat higher cumulative incidence rates of MR4.5 at M36 versus Nilotinib alone in newly diagnosed CP CML patients. Updated results of the Petals Phase III national study","volume":"134","author":"Nicolini","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.004_bib0059","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood.V130.Suppl_1.899.899","article-title":"Nilotinib versus Nilotinib combined to pegylated-interferon alfa 2a in first-line chronic phase chronic myelogenous leukemia patients. Interim analysis of a phase III trial","volume":"130","author":"Nicolini","year":"2017","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.004_bib0060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2023-182792","article-title":"Treatment free remission after Nilotinib plus peg-interferon alpha induction and peg-interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients; the Tiger trial","volume":"142","author":"Hochhaus","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.004_bib0061","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2022-169324","article-title":"Efficacy of Ropeginterferon Alpha 2b in inducing treatment free remission in chronic myeloid leukemia - an international, randomized phase III trial (ENDURE, CML-IX) of the German CML-Study Group","volume":"140","author":"Buchert","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2025.01.004_bib0063","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1182\/blood-2006-06-026377","article-title":"Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias","volume":"109","author":"Weisberg","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.01.004_bib0064","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance","volume":"102","author":"Burgess","year":"2005","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10.1016\/j.clml.2025.01.004_bib0065","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)\u2013based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.01.004_bib0066","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1\u2013mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.01.004_bib0067","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/10245332.2015.1119369","article-title":"Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure","volume":"21","author":"G\u00f3mez-Almaguer","year":"2016","journal-title":"Hematology"},{"issue":"7647","key":"10.1016\/j.clml.2025.01.004_bib0068","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0069","doi-asserted-by":"crossref","first-page":"e1214","DOI":"10.1002\/prp2.1214","article-title":"Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance","volume":"12","author":"Okamoto","year":"2024","journal-title":"Pharmacol Res Perspect"},{"issue":"S1","key":"10.1016\/j.clml.2025.01.004_bib0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.HS9.0000561812.22500.d8","article-title":"S883 Combination therapy using asciminib plus imatinib (IMA) in patients (pts) with cronic myeloid leukemia (CML): results from a phase 1 study","volume":"3","author":"Cortes","year":"2019","journal-title":"HemaSphere"},{"issue":"S1","key":"10.1016\/j.clml.2025.01.004_bib0071","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.HS9.0000561816.04574.8b","article-title":"S884 Combination of asciminib plus nilotinib (NIL) or dasatinib (DAS) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study","volume":"3","author":"Mauro","year":"2019","journal-title":"Hemasphere"},{"issue":"S3","key":"10.1016\/j.clml.2025.01.004_bib0072","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/01.HS9.0000967536.34543.a6","article-title":"S156 Frontline asciminib combination in chronic phase chronic myeloid leukemia patients. The FASCINATION trial","volume":"7","author":"Ernst","year":"2023","journal-title":"HemaSphere"},{"issue":"19","key":"10.1016\/j.clml.2025.01.004_bib0073","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood.2024024657","article-title":"Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study","volume":"144","author":"Yeung","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.01.004_bib0074","unstructured":"Yeung D.T., Shanmuganathan N., Yong A.S.M., et al. Update of the Ascend-CML study of frontline asciminib: high rate of optimal response and resistance due to mutations is rare. Oral and poster abstracts, 632. Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice, 2024. ASH Annual Meeting; San Diego, CA. Available from: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper201218.html. Accessed December 5, 2024."},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2022-167177","volume":"140","author":"Cortes","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.01.004_bib0076","doi-asserted-by":"crossref","first-page":"9643","DOI":"10.1182\/blood-2022-157002","article-title":"A phase II, single-arm study of de-escalation and treatment-free remission in patients with chronic myeloid leukemia treated with Nilotinib in first-line therapy followed by a second attempt after Nilotinib and Asciminib combination: dante Study","volume":"140","author":"Rosti","year":"2022","journal-title":"Blood"},{"issue":"355","key":"10.1016\/j.clml.2025.01.004_bib0077","doi-asserted-by":"crossref","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci Transl Med"},{"issue":"19","key":"10.1016\/j.clml.2025.01.004_bib0078","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.18632\/oncotarget.1925","article-title":"The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors","volume":"5","author":"Ko","year":"2014","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.clml.2025.01.004_bib0079","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1159\/000506346","article-title":"Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias","volume":"143","author":"Maiti","year":"2020","journal-title":"Acta Haematol"},{"issue":"15","key":"10.1016\/j.clml.2025.01.004_bib0080","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1002\/cncr.35317","article-title":"Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia","volume":"130","author":"Jabbour","year":"2024","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.clml.2025.01.004_bib0081","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137093","article-title":"Targeting leukemic stem cells in chronic myeloid leukemia: is it worth the effort?","volume":"22","author":"Soverini","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"S1","key":"10.1016\/j.clml.2025.01.004_bib0082","first-page":"159","article-title":"(S174) A phase 2, randomized trial of ruxolitinib in addition to BCR::ABL1 TKIs in CML patients with molecular evidence of disease (SWOG TRIAL S1712)","volume":"8","author":"Sweet","year":"2024","journal-title":"HemaSphere"},{"issue":"7569","key":"10.1016\/j.clml.2025.01.004_bib0083","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.clml.2025.01.004_bib0084","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.clml.2025.01.004_bib0085","doi-asserted-by":"crossref","first-page":"E321","DOI":"10.1002\/ajh.25986","article-title":"Efficacy and safety of pioglitazone in a phase 1\/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response","volume":"95","author":"Pagnano","year":"2020","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0086","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1182\/blood-2022-164598","article-title":"Five-year follow-up of the phase I\/II discontinuation trial of Imatinib after Pioglitazone (EDI-PIO) in chronic myeloid leukemia patients in deep molecular response","volume":"140","author":"Pagnano","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0087","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00432-024-05700-x","article-title":"Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes","volume":"150","author":"Tian","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.01.004_bib0088","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1073\/pnas.0813142106","article-title":"A systems biology understanding of the synergistic effects of arsenic sulfide and imatinib in BCR\/ABL-associated leukemia","volume":"106","author":"Zhang","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2025.01.004_bib0089","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune effector recovery in chronic myeloid leukemia and treatment-free remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.clml.2025.01.004_bib0090","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1007\/s00277-024-06074-3","article-title":"Immune checkpoints PD1\/PDL1, TIM3\/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia","volume":"103","author":"Toloza","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0091","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1182\/blood-2021-145015","article-title":"Minimal toxicity seen when pembrolizumab is added to tyrosine kinase inhibitors in patients with chronic myeloid leukemia and persistently detectable minimal residual disease: early results from an ongoing phase II trial (ECOG-ACRIN EA9171)","volume":"138","author":"Zeidan","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.01.004_bib0092","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1080\/10428194.2021.1889536","article-title":"The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study","volume":"62","author":"Martinez-Lopez","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0093","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1475-2867-12-52","article-title":"New insights into antigen specific immunotherapy for chronic myeloid leukemia","volume":"12","author":"Li","year":"2012","journal-title":"Cancer Cell Int"},{"issue":"11","key":"10.1016\/j.clml.2025.01.004_bib0094","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2025.01.004_bib0095","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nrclinonc.2010.141","article-title":"Complete molecular response in CML after p210 BCR\u2013ABL1-derived peptide vaccination","volume":"7","author":"Bocchia","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"9460","key":"10.1016\/j.clml.2025.01.004_bib0096","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.01.004_bib0097","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.exphem.2017.09.012","article-title":"Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in ph+ chronic myeloid leukemia","volume":"57","author":"Willmann","year":"2018","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.01.004_bib0098","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3324\/haematol.2019.230227","article-title":"Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells","volume":"106","author":"Yahata","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0099","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1002\/cam4.5292","article-title":"Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor","volume":"12","author":"Takahashi","year":"2023","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.clml.2025.01.004_bib0100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1158\/0008-5472.CAN-18-1078","article-title":"CML hematopoietic stem cells expressing IL1RAP can Be targeted by chimeric antigen receptor-engineered T cells","volume":"79","author":"Warda","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2025.01.004_bib0101","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2147\/OTT.S255299","article-title":"Identification and targeting of Thomsen-Friedenreich and IL1RAP antigens on chronic myeloid leukemia stem cells using Bi-specific antibodies","volume":"14","author":"Eldesouki","year":"2021","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0102","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41375-020-0824-y","article-title":"A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells","volume":"35","author":"Zhou","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.01.004_bib0103","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/cancers13061311","article-title":"Targeting chronic myeloid leukemia stem\/progenitor cells using venetoclax-loaded immunoliposome","volume":"13","author":"Houshmand","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clml.2025.01.004_bib0104","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3324\/haematol.2018.212365","article-title":"The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL\/TAL1 - CD44 axis","volume":"105","author":"Godavarthy","year":"2020","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.clml.2025.01.004_bib0106","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1182\/blood-2015-11-679928","article-title":"Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells","volume":"128","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.01.004_bib0107","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1186\/s12885-019-5871-2","article-title":"Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia","volume":"19","author":"Herrmann","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.clml.2025.01.004_bib0108","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3324\/haematol.2019.219261","article-title":"Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model","volume":"105","author":"Carter","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.01.004_bib0109","first-page":"483","article-title":"HDAC I\/IIb selective inhibitor purinostat mesylate combined with GLS1 inhibition effectively eliminates CML stem cells","volume":"21","author":"Qiu","year":"2022","journal-title":"Bioact Mater"},{"issue":"5","key":"10.1016\/j.clml.2025.01.004_bib0110","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/cbin.11557","article-title":"Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: new insight into attenuating effects of the PI3K\/c-Myc axis on panobinostat cytotoxicity","volume":"45","author":"Zehtabcheh","year":"2021","journal-title":"Cell Biol Int"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0111","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1007\/s13577-023-00919-1","article-title":"HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt-autophagy pathway","volume":"36","author":"Yin","year":"2023","journal-title":"Hum Cell"},{"issue":"11","key":"10.1016\/j.clml.2025.01.004_bib0112","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-16-0263","article-title":"Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition","volume":"6","author":"Scott","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.clml.2025.01.004_bib0113","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/nano10020276","article-title":"Nanocarriers as magic bullets in the treatment of leukemia","volume":"10","author":"Houshmand","year":"2020","journal-title":"Nanomaterials"},{"issue":"9","key":"10.1016\/j.clml.2025.01.004_bib0114","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.3390\/molecules25092193","article-title":"Therapeutic nanoparticles and their targeted delivery applications","volume":"25","author":"Yetisgin","year":"2020","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.clml.2025.01.004_bib0115","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3390\/ph17070894","article-title":"Enhanced antitumor activity by the combination of Dasatinib and Selinexor in chronic myeloid leukemia","volume":"17","author":"Spampinato","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.clml.2025.01.004_bib0116","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3324\/haematol.2022.280922","article-title":"Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition","volume":"108","author":"B\u00fctow","year":"2023","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T20:26:23Z","timestamp":1747686383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":116,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2152265025000151"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Combination Therapy in Chronic Myeloid Leukemia in Chronic Phase","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}